【摘要】 目的:观察中晚期肿瘤患者应用薄芝糖肽注射液前后T淋巴细胞亚群和NK细胞变化,进一步探讨其抗肿瘤活性。方法:60例确诊为中晚期恶性肿瘤的住院患者随机分组,治疗组30人,对照组30人,对比2组患者治疗前后T淋巴细胞亚群(CD3、CD4、CD8)和NK细胞绝对数值。结果:2组患者对比结果表明,测定治疗后1月、2月、3月检测T淋巴细胞亚群和NK细胞绝对值,同时测定患者功能状态(KPS)评分及无进展生存期(PFS),具有统计学意义。结论:薄芝糖肽注射液能够明显促进晚期癌症患者CD3、CD4细胞及NK细胞增殖,CD8下降,CD4/CD8比值升高,从而提高患者机体免疫功能,抑制肿瘤细胞活性,改善生活质量。更多还原

【Abstract】 Objective: To observe the advanced cancer patients with Bozhi Glycopeptide Injection before and after T lymphocyte subsets and N K cells change, to further explore the anti-tumor activity. Methods: 60 cases were diagnosed as malignant tumor in middle and advanced stage of hospitalized patients were randomly divided into two groups, treatment group, 30, 30 in the control group, compared two groups of patients before and after treatment of T lymphocyte subsets(CD3, CD4, CD8) and NK cells absolute numerical. Results: The 2 groups were compared results show that determination of treatment after January, 2 months, 3 months to detect T lymphocyte subsets and N K cells absolute value of simultaneous determination of patient functional status(KPS) and progression free survival(PFS), with statistical significance. Conclusion: Bozhi Glycopeptide Injection can obviously promote the late cancer patients CD3, CD4 + and CD8 + T cells and NK cell proliferation, decreased CD8, CD4 / CD8 ratio increased, so as to improve the immune function of patients, inhibit tumor cell activity, improve quality of life.更多还原